Evidence map›Paper›PMID 42733742›Full record

ArticleInfectious medicine2026

Preparation and characterization of the affinity and neutralization abilities of human monoclonal antibodies against bunyavirus SFTSV glycoprotein C.

Jingxian Liu, Yuhan Ding, Yuheng Zhu, Ying Chi, Chao Huang, Yin Chen, Fengjuan Shi, Yan Xu, Minghui Fu, Lunbiao Cui and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infectious medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jingxian LiuNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China.
Yuhan DingNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China.
Yuheng ZhuSchool of Biological Science and Medical Engineering, Southeast University, Nanjing, 210009, China.
Ying ChiNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China.
Chao HuangNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China.
Yin ChenNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China.
Fengjuan ShiNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China.
Yan XuNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China.
Minghui FuNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China.
Lunbiao CuiNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China.
Yongjun JiaoNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Severe fever with thrombocytopenia syndrome (SFTS) caused by severe fever with thrombocytopenia syndrome virus (SFTSV) has become a persistent threat to public health. Since neutralizing monoclonal antibody therapy can invoke an immediate and effective passive immunity, endeavours made to discover the therapeutic monoclonal antibodies should be worthwhile. This study aimed to screen and purify the human monoclonal antibodies (hmAbs) against SFTSV glycoprotein C and characterize the properties of the hmAbs. Methods: Human monoclonal antibodies against SFTSV glycoprotein C (Gc) were prepared from the convalescent SFTS patients' lymphocytes using the phage display technology. A single-chain variable fragment antibody library against SFTSV Gc was successfully constructed, and two specific single-chain variable fragment antibodies were screened and expressed as hmAbs immunoglobulin G (IgG) (hIgG4 and hIgG5). Results: Enzyme-linked immunosorbent assay, Western blot and immunofluorescence assay test results confirmed that both hIgG4 and hIgG5 specifically bound to SFTSV Gc antigen and intact SFTSV virions. The neutralization test showed that both hmAbs exhibited broad-spectrum neutralizing activity against three SFTSV strains with different genotypes (A, E and F) Conclusions: hIgG4 and hIgG5 possess potent neutralizing effects, showing great potential as candidate therapeutic hmAbs for SFTS treatment.

Indexed as

Broad-spectrum neutralizing activityGlycoprotein ChmAbsSevere fever with thrombocytopenia syndromeSevere fever with thrombocytopenia syndrome virus

Identifiers

PMID42733742
PMCPMC13571492

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.